Scope of the Study
Rapid growth in cases of rare diseases, as well as demand for a personalized drug, will help to boost global AI for the drug discovery market. Artificial intelligence (AI) for drug discovery is a technology that uses and different algorithms that value add in decision-making procedures for drug discovery. This technology has the ability to identify drug targets and play a vital role in drug discovery, design, identification, and screening of molecules instantly and effectively. Growing demand in the untapped market will help to fuel market demand.
The market study is being classified and major geographies with country level break-up.
Atomwise, Inc. (United States), Insilico Medicine (United States), BIOAGE (United States), Envisagenics (New York), Cloud Pharmaceuticals, Inc. (United States), Numerate (United States), NuMedii, Inc. (United States), BenevolentAI (United Kingdom), twoXAR, Incorporated (United States) and Exscientia (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Globavir, Inc. (United States) and Tute Genomics (PierianDx, Inc.) (United States).
The Players having a strong hold in the market are Atomwise, Inc.. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global AI for Drug Discovery market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global AI for Drug Discovery market by Type, Application and Region.
On the basis of geography, the market of AI for Drug Discovery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Drug Type, the sub-segment i.e. Small Molecule will boost the AI for Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic Type, the sub-segment i.e. Metabolic Disease will boost the AI for Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Deep Learning will boost the AI for Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Pharmaceutical Companies will boost the AI for Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Demand Due To Reduction in Price
- High Adoption Due To AI Reduces Researches and Development Gap in the Drug Manufacturing Process
- Growing Number of Cross-Industry Partnerships & Collaborations
- Upsurge In Capital of the R&D Activities for the Use of AI Technology
- High Cost and Technical Limitations
- Rising Awareness about AI for Drug Discovery
- Huge Demand from Untapped Market
- Reluctance among Medical Practitioners to Adopt AI-Based Technologies
Market Leaders and their expansionary development strategies
On 16th April 2019, Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization working to deliver new treatments for neglected diseases has launched promising drug-like compounds have been discovered in a program to develop first-in-class treatments for Chagas disease. The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program.
On 30th May 2018, Cloud Pharmaceuticals, Inc., an Artificial Intelligence-driven drug design and Development Company has collaborated with GlaxoSmithKline (GSK). Cloud will design novel small-molecule agents to GSK specified targets. Cloud will use its proprietary AI-driven process to design the molecules.
Key Target AudienceAI for Drug Discovery Providers, Pharmaceutical Companies, Medical Associations, Technology Developers, Government Regulatory Bodies, Private and Government Research Organizations and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase